ATRC - CIK 0001323885
The table below shows AtriCure, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $57.33M | $12.20M | $4.48M | -$22.14M | -$13.78M | -$19.87M |
| Capital expenditure | $9.05M | $11.46M | $12.00M | $16.88M | $9.75M | $5.26M |
| Investing cash flow | -$14.55M | $30.23M | $21.82M | $44.01M | $23.50M | -$156.20M |
| Dividends paid | - | - | - | - | - | - |
AtriCure, Inc. reported operating cash flow of $57.33M for fiscal year 2025. That is up 369.8% from $12.20M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$15.12M (FY 2016) to $57.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.18M | -$3.60M | -$32.00K | -$7.06M | -$7.64M | $189.39M |